Oncology
Myeloid Malignancies
0
Pipeline Programs↗
15
Active Trials↗
11
Companies Involved↗
Myeloid Malignancies is an early-stage landscape with 0 programs across 11 companies. The most active players are Amgen, Aprea Therapeutics, Beijing InnoCare Pharma Tech Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
41
clinical trials
Completed17 · 41%
Recruiting13 · 32%
Unknown status5 · 12%
Terminated4 · 10%
Not yet recruiting2 · 5%
Clinical Trials
Trial Activity
41 trials
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT05841771·78 enrolled
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
Recruiting·—·Phase 1·NCT04187703·20 enrolled
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT07052422·160 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)